SPH3127

SPH3127 (DRI 18) is a novel, highly potent, and orally active direct renin inhibitor (recombinant human-renin IC 50 =0.4 nM, human plasma renin activity IC 50 =0.45 nM). SPH3127 shows antihypertensive effect and can be used in essential hypertension research. In Vivo SPH3127 (oral administration; 0-10 mg/kg; once) shows favorable bioavailability in cynomolgus monkeys . SPH3127 (oral administration; 0-3 mg/kg; once) shows a hypotensive effect on tsukuba hypertensive mice . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Cynomolgus monkeys pretreated with a low-sodium diet and furosemide Dosage: 0, 1, 3, and 10 mg/kg Administration: Oral administration; 1, 3, and 10 mg/kg; once Result: Inhibited plasma renin activity with the IC 50 value of 0.46 nM, and showed hypotensive effect. Animal Model: Tsukuba hypertensive mice (THM) Dosage: 0, 0.3, 1, or 3 mg/kg Administration: Oral administration; 0, 0.3, 1, or 3 mg/kg; once Result: Exhibited a hypotensive effect on tsukuba hypertensive mice in a dose-dependent manner from 0.3 to 3 mg/kg, and showed a maximum hypotensive effect of approximately 30 mmHg at 2-3 h after administration at any dose. Form:Solid

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet